Breaking News: FDA Gives Green Light to Coherus’ Cimerli (Ranibizumab EQRN) as the First Interchangeable Biosimilar to Lucentis for All 5 Indications with 12 Months of Interchangeability Exclusivity!
FDA Approves Coherus’ CIMERLI™ Introducing Coherus’ Latest FDA Approved Product Coherus Biosciences, a leading biotechnology company, has received FDA approval for their newest product, CIMERLI™. This marks Coherus’ third FDA-approved product and is the first of four new product launches planned by the end of 2023. The launch of CIMERLI™ is highly anticipated in the…